Brussels, 26/07/2011 (Agence Europe) - OLAF, the European Anti-Fraud Office, announced on Monday 25 July that it had opened an investigation into possible conflicts of interest in the European Medicines Agency (EMA) in the Mediator issue. Mediator is a medicine for overweight diabetics, also prescribed as an appetite suppressant, which was withdrawn from the Spanish, Italian and French markets after serious side-effects were noted which caused the deaths of hundreds of patients.
In an email...